Currently, the treatment of choice in Europe and USA for Head and Neck Squamous Cell Carcinoma (HNSCC), especially for elderly (>65 years old), frail, or unfit for cisplatin patients, consists in systemic administration of Cetuximab (a monoclonal antibody that inhibits EGFR) in combination with radiotherapy (RT) [89,90]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.